From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
HGF (pM)
EGF (pM)
Fraction activated (%)
Combination Index
50
300
92.8
1.43
10
60
58.9
1.81
2
12
25.7
1.25
0.4
2.4
8.7
0.8